192 related articles for article (PubMed ID: 26519543)
1. Electrophysiologic features of SYT2 mutations causing a treatable neuromuscular syndrome.
Whittaker RG; Herrmann DN; Bansagi B; Hasan BA; Lofra RM; Logigian EL; Sowden JE; Almodovar JL; Littleton JT; Zuchner S; Horvath R; Lochmüller H
Neurology; 2015 Dec; 85(22):1964-71. PubMed ID: 26519543
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up in patients with congenital myasthenic syndrome due to RAPSN mutations.
Natera-de Benito D; Bestué M; Vilchez JJ; Evangelista T; Töpf A; García-Ribes A; Trujillo-Tiebas MJ; García-Hoyos M; Ortez C; Camacho A; Jiménez E; Dusl M; Abicht A; Lochmüller H; Colomer J; Nascimento A
Neuromuscul Disord; 2016 Feb; 26(2):153-9. PubMed ID: 26782015
[TBL] [Abstract][Full Text] [Related]
3. Biallelic loss of function variants in SYT2 cause a treatable congenital onset presynaptic myasthenic syndrome.
Donkervoort S; Mohassel P; Laugwitz L; Zaki MS; Kamsteeg EJ; Maroofian R; Chao KR; Verschuuren-Bemelmans CC; Horber V; Fock AJM; McCarty RM; Jain MS; Biancavilla V; McMacken G; Nalls M; Voermans NC; Elbendary HM; Snyder M; Cai C; Lehky TJ; Stanley V; Iannaccone ST; Foley AR; Lochmüller H; Gleeson J; Houlden H; Haack TB; Horvath R; Bönnemann CG
Am J Med Genet A; 2020 Oct; 182(10):2272-2283. PubMed ID: 32776697
[TBL] [Abstract][Full Text] [Related]
4. Novel truncating RAPSN mutations causing congenital myasthenic syndrome responsive to 3,4-diaminopyridine.
Banwell BL; Ohno K; Sieb JP; Engel AG
Neuromuscul Disord; 2004 Mar; 14(3):202-7. PubMed ID: 15036330
[TBL] [Abstract][Full Text] [Related]
5. Clinical features of congenital myasthenic syndrome due to mutations in DPAGT1.
Finlayson S; Palace J; Belaya K; Walls TJ; Norwood F; Burke G; Holton JL; Pascual-Pascual SI; Cossins J; Beeson D
J Neurol Neurosurg Psychiatry; 2013 Oct; 84(10):1119-25. PubMed ID: 23447650
[TBL] [Abstract][Full Text] [Related]
6. Distinct phenotypes of congenital acetylcholine receptor deficiency.
Burke G; Cossins J; Maxwell S; Robb S; Nicolle M; Vincent A; Newsom-Davis J; Palace J; Beeson D
Neuromuscul Disord; 2004 Jun; 14(6):356-64. PubMed ID: 15145336
[TBL] [Abstract][Full Text] [Related]
7. Synaptotagmin 2 mutations cause an autosomal-dominant form of lambert-eaton myasthenic syndrome and nonprogressive motor neuropathy.
Herrmann DN; Horvath R; Sowden JE; Gonzalez M; Sanchez-Mejias A; Guan Z; Whittaker RG; Almodovar JL; Lane M; Bansagi B; Pyle A; Boczonadi V; Lochmüller H; Griffin H; Chinnery PF; Lloyd TE; Littleton JT; Zuchner S
Am J Hum Genet; 2014 Sep; 95(3):332-9. PubMed ID: 25192047
[TBL] [Abstract][Full Text] [Related]
8. Mutations in DPAGT1 cause a limb-girdle congenital myasthenic syndrome with tubular aggregates.
Belaya K; Finlayson S; Slater CR; Cossins J; Liu WW; Maxwell S; McGowan SJ; Maslau S; Twigg SR; Walls TJ; Pascual Pascual SI; Palace J; Beeson D
Am J Hum Genet; 2012 Jul; 91(1):193-201. PubMed ID: 22742743
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of Lambert-Eaton syndrome with 3,4- diaminopyridine and pyridostigmine].
Yachachi Monfort A; Cortés Pastor F; de la Rubia Nieto A; Sánchez Garre MJ
Farm Hosp; 2007; 31(4):254-6. PubMed ID: 18052623
[No Abstract] [Full Text] [Related]
10. Recessive congenital myasthenic syndrome caused by a homozygous mutation in SYT2 altering a highly conserved C-terminal amino acid sequence.
Maselli RA; van der Linden H; Ferns M
Am J Med Genet A; 2020 Jul; 182(7):1744-1749. PubMed ID: 32250532
[TBL] [Abstract][Full Text] [Related]
11. A Cys-loop mutation in the Caenorhabditis elegans nicotinic receptor subunit UNC-63 impairs but does not abolish channel function.
Jones AK; Rayes D; Al-Diwani A; Maynard TP; Jones R; Hernando G; Buckingham SD; Bouzat C; Sattelle DB
J Biol Chem; 2011 Jan; 286(4):2550-8. PubMed ID: 20966081
[TBL] [Abstract][Full Text] [Related]
12. Dominant and recessive congenital myasthenic syndromes caused by SYT2 mutations.
Maselli RA; Wei DT; Hodgson TS; Sampson JB; Vazquez J; Smith HL; Pytel P; Ferns M
Muscle Nerve; 2021 Aug; 64(2):219-224. PubMed ID: 34037996
[TBL] [Abstract][Full Text] [Related]
13. Treatment for Lambert-Eaton myasthenic syndrome.
Keogh M; Sedehizadeh S; Maddison P
Cochrane Database Syst Rev; 2011 Feb; 2011(2):CD003279. PubMed ID: 21328260
[TBL] [Abstract][Full Text] [Related]
14. Amifampridine phosphate in congenital myasthenic syndrome.
Verma S; Mazell SN; Shah DA
Muscle Nerve; 2016 Oct; 54(4):809-10. PubMed ID: 27348204
[No Abstract] [Full Text] [Related]
15. A new de novo SYT2 mutation presenting as distal weakness. Neuropathy or neuromuscular junction dysfunction?
Fionda L; Turon-Sans J; Fuentes Prior P; Bernal Noguera S; Cortés-Vicente E; López-Pérez MA; Gallardo E; Rojas-García R
J Peripher Nerv Syst; 2021 Mar; 26(1):113-117. PubMed ID: 33320396
[TBL] [Abstract][Full Text] [Related]
16. Recurrent COLQ mutation in congenital myasthenic syndrome.
Guven A; Demirci M; Anlar B
Pediatr Neurol; 2012 Apr; 46(4):253-6. PubMed ID: 22490774
[TBL] [Abstract][Full Text] [Related]
17. Clinical features in a series of fast channel congenital myasthenia syndrome.
Palace J; Lashley D; Bailey S; Jayawant S; Carr A; McConville J; Robb S; Beeson D
Neuromuscul Disord; 2012 Feb; 22(2):112-7. PubMed ID: 21940170
[TBL] [Abstract][Full Text] [Related]
18. [Beneficial effects of 3,4-diaminopyridine in a 26-year-old woman with DOK7 congenital myasthenic syndrome who was originally diagnosed with facioscapulohumeral dystrophy].
Nishikawa A; Mori-Yoshimura M; Okamoto T; Oya Y; Nakata T; Ohno K; Murata M
Rinsho Shinkeigaku; 2014; 54(7):561-4. PubMed ID: 25087557
[TBL] [Abstract][Full Text] [Related]
19. 3,4-Diaminopyridine for the treatment of myasthenia gravis with electrophysiological patterns of Lambert-Eaton myasthenic syndrome.
Lee MK; Sunwoo IN; Kim SM
J Clin Neurosci; 2018 Apr; 50():194-198. PubMed ID: 29402568
[TBL] [Abstract][Full Text] [Related]
20. Treatment for Lambert-Eaton myasthenic syndrome.
Maddison P; Newsom-Davis J
Cochrane Database Syst Rev; 2003; (2):CD003279. PubMed ID: 12804456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
